Line 368: |
Line 368: |
| |Acute myeloid leukaemia with CEBPA mutation | | |Acute myeloid leukaemia with CEBPA mutation |
| |Disease | | |Disease |
− | |Paul Defazio, MSc, Monash Health | + | | |
| | | | | |
| | | | | |
Line 376: |
Line 376: |
| | | | | |
| | | | | |
− | | | + | |Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA |
− | | | + | |Paul Defazio, MSc, Monash Health |
− | | | + | |Complete |
| | | | | |
| | | | | |
Line 384: |
Line 384: |
| |Acute myeloid leukaemia, myelodysplasia-related | | |Acute myeloid leukaemia, myelodysplasia-related |
| |Disease | | |Disease |
− | |Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR | + | | |
| | | | | |
| | | | | |
Line 392: |
Line 392: |
| | | | | |
| | | | | |
− | | | + | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes |
− | | | + | |Fei Yang, MD, FACMG <br> Oregon Health & Science University |
− | | | + | |Complete |
| | | | | |
| | | | | |
Line 408: |
Line 408: |
| | | | | |
| | | | | |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| |- | | |- |
| |Acute myeloid leukaemia with minimal differentiation | | |Acute myeloid leukaemia with minimal differentiation |
Line 424: |
Line 424: |
| | | | | |
| | | | | |
− | | | + | |Acute Myeloid Leukemia (AML) with Minimal Differentiation |
− | | | + | |Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine |
− | | | + | |Complete |
| | | | | |
| | | | | |
Line 440: |
Line 440: |
| | | | | |
| | | | | |
− | | | + | |Acute Myeloid Leukemia (AML) without Maturation |
− | | | + | |Jennelle C. Hodge, PhD, FACMG |
− | | | + | |Complete |
| | | | | |
| | | | | |
Line 456: |
Line 456: |
| | | | | |
| | | | | |
− | | | + | |Acute Myeloid Leukemia (AML) with Maturation |
− | | | + | |Jennelle C. Hodge, PhD, FACMG |
− | | | + | |Complete |
| | | | | |
| | | | | |